These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

799 related articles for article (PubMed ID: 33994936)

  • 1. Glycolytic Metabolism, Brain Resilience, and Alzheimer's Disease.
    Zhang X; Alshakhshir N; Zhao L
    Front Neurosci; 2021; 15():662242. PubMed ID: 33994936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opposing Effects of ApoE2 and ApoE4 on Glycolytic Metabolism in Neuronal Aging Supports a Warburg Neuroprotective Cascade against Alzheimer's Disease.
    Zhang X; Wu L; Swerdlow RH; Zhao L
    Cells; 2023 Jan; 12(3):. PubMed ID: 36766752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human ApoE Isoforms Differentially Modulate Brain Glucose and Ketone Body Metabolism: Implications for Alzheimer's Disease Risk Reduction and Early Intervention.
    Wu L; Zhang X; Zhao L
    J Neurosci; 2018 Jul; 38(30):6665-6681. PubMed ID: 29967007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human ApoE Isoforms Differentially Modulate Glucose and Amyloid Metabolic Pathways in Female Brain: Evidence of the Mechanism of Neuroprotection by ApoE2 and Implications for Alzheimer's Disease Prevention and Early Intervention.
    Keeney JT; Ibrahimi S; Zhao L
    J Alzheimers Dis; 2015; 48(2):411-24. PubMed ID: 26402005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of Small Molecule Glycolytic Stimulants for Enhanced ApoE Lipidation in Alzheimer's Disease Cell Model.
    Patil SP; Kuehn BR
    Pharmaceuticals (Basel); 2024 Apr; 17(4):. PubMed ID: 38675451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human ApoE ɛ2 Promotes Regulatory Mechanisms of Bioenergetic and Synaptic Function in Female Brain: A Focus on V-type H+-ATPase.
    Woody SK; Zhou H; Ibrahimi S; Dong Y; Zhao L
    J Alzheimers Dis; 2016 Jun; 53(3):1015-31. PubMed ID: 27340853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the Role of Glycolytic Enzymes PFKFB3 and GAPDH in the Modulation of Aβ and Neurodegeneration and Their Potential of Therapeutic Targets in Alzheimer's Disease.
    Ahmad I; Singh R; Pal S; Prajapati S; Sachan N; Laiq Y; Husain H
    Appl Biochem Biotechnol; 2023 Jul; 195(7):4673-4688. PubMed ID: 36692648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases.
    Fernández-Calle R; Konings SC; Frontiñán-Rubio J; García-Revilla J; Camprubí-Ferrer L; Svensson M; Martinson I; Boza-Serrano A; Venero JL; Nielsen HM; Gouras GK; Deierborg T
    Mol Neurodegener; 2022 Sep; 17(1):62. PubMed ID: 36153580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of apolipoprotein E isoforms on sporadic Alzheimer's disease: beyond the role of amyloid beta.
    Lozupone M; Panza F
    Neural Regen Res; 2024 Jan; 19(1):80-83. PubMed ID: 37488848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential Signaling Mediated by ApoE2, ApoE3, and ApoE4 in Human Neurons Parallels Alzheimer's Disease Risk.
    Huang YA; Zhou B; Nabet AM; Wernig M; Südhof TC
    J Neurosci; 2019 Sep; 39(37):7408-7427. PubMed ID: 31331998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APOE and Alzheimer's Disease: Evidence Mounts that Targeting APOE4 may Combat Alzheimer's Pathogenesis.
    Uddin MS; Kabir MT; Al Mamun A; Abdel-Daim MM; Barreto GE; Ashraf GM
    Mol Neurobiol; 2019 Apr; 56(4):2450-2465. PubMed ID: 30032423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axonal energy metabolism, and the effects in aging and neurodegenerative diseases.
    Yang S; Park JH; Lu HC
    Mol Neurodegener; 2023 Jul; 18(1):49. PubMed ID: 37475056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APOΕ4 lowers energy expenditure in females and impairs glucose oxidation by increasing flux through aerobic glycolysis.
    Farmer BC; Williams HC; Devanney NA; Piron MA; Nation GK; Carter DJ; Walsh AE; Khanal R; Young LEA; Kluemper JC; Hernandez G; Allenger EJ; Mooney R; Golden LR; Smith CT; Brandon JA; Gupta VA; Kern PA; Gentry MS; Morganti JM; Sun RC; Johnson LA
    Mol Neurodegener; 2021 Sep; 16(1):62. PubMed ID: 34488832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APOE alters glucose flux through central carbon pathways in astrocytes.
    Williams HC; Farmer BC; Piron MA; Walsh AE; Bruntz RC; Gentry MS; Sun RC; Johnson LA
    Neurobiol Dis; 2020 Mar; 136():104742. PubMed ID: 31931141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of apolipoprotein E polymorphism as a prognostic marker in traumatic brain injury and neurodegenerative disease: a critical review.
    Maiti TK; Konar S; Bir S; Kalakoti P; Bollam P; Nanda A
    Neurosurg Focus; 2015 Nov; 39(5):E3. PubMed ID: 26646927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer's disease?
    Vecchio FL; Bisceglia P; Imbimbo BP; Lozupone M; Latino RR; Resta E; Leone M; Solfrizzi V; Greco A; Daniele A; Watling M; Panza F; Seripa D
    Ther Adv Chronic Dis; 2022; 13():20406223221081605. PubMed ID: 35321401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
    Chen Z; Zhong C
    Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ApoE: the link between Alzheimer's-related glucose hypometabolism and Aβ deposition?
    Patil SP; Ballard R; Sanchez S; Osborn J; Santangelo D
    Med Hypotheses; 2012 Apr; 78(4):494-6. PubMed ID: 22285195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebral hypoperfusion and glucose hypometabolism: Key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer's disease.
    Daulatzai MA
    J Neurosci Res; 2017 Apr; 95(4):943-972. PubMed ID: 27350397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.